Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Lupin is currently trading at Rs 425.05, up by 12.25 points or 2.97% from its previous closing of Rs 412.80 on the BSE.
The scrip opened at Rs 411.00 and has touched a high and low of Rs 426.90 and Rs 410.10 respectively. So far 51672 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 495.00 on 06-Jan-2011 and a 52 week low of Rs 363.00 on 25-Feb-2011.
Last one week high and low of the scrip stood at Rs 449.00 and Rs 409.50 respectively. The current market cap of the company is Rs 18435.09 crore.
The promoters holding in the company stood at 46.94% while Institutions and Non-Institutions held 43.33% and 9.72% respectively.
Pharma Major, Lupin’s US subsidiary - Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Duloxetine Hydrochloride Delayed-release (HCL DR) Capsules 20 mg, 30 mg and 60 mg from the United States Food and Drugs Administration (USFDA) for the company's Abbreviated New Drug Application (ANDA) to market a generic version of Eli Lily & Company's Cymbalta Delayed-release Capsules.
Lupin's Duloxetine HCL DR Capsules are the AB-rated generic equivalent of Eli Lily's Cymbalta Delayed-release Capsules 20 mg, 30 mg and 60 mg strengths. Duloxetine HCL DR Capsules is indicated for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), management of neuropathic pain. (DPNP) associated with diabetic peripheral neuropathy, management of fibromyalgia (FM) and management of chronic musculoskeletal pain.
Cymbalta HCL DR Capsules 20 mg, 30 mg, 60 mg had annual US sales of approximately $33 billion for the twelve months ending September, 2011 as per IMS Health data.
Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1487.45 |
| Dr. Reddys Lab | 5822.90 |
| Cipla | 1497.85 |
| Zydus Lifesciences | 1049.75 |
| Lupin | 1630.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
